Status:

COMPLETED

Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial

Lead Sponsor:

GWT-TUD GmbH

Conditions:

Metabolic Syndrome

Eligibility:

All Genders

40-70 years

Phase:

PHASE3

Brief Summary

The aim of the study was to analyse the independent and joint effects of the components of the metabolic syndrome (MetS) on the incidence of diabetes in people with impaired glucose tolerance (IGT) an...

Eligibility Criteria

Inclusion

  • High risk population
  • Age 40 to 70 yrs.
  • BMI \> 25 and \< 40; FPG \>5.5 mmol/l and \< 7.8 mmol/l; IGT in OGGT

Exclusion

  • Known type 2 diabetes
  • Drug intake affecting glucose tolerance
  • Any cardiovascular events within the last 6 months

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

1429 Patients enrolled

Trial Details

Trial ID

NCT00629213

Last Update

March 7 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

GWT-TUD GmbH

Dresden, Saxony, Germany, 01187

Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial | DecenTrialz